For the Quarter Ending March 2026
Clopidogrel Prices in APAC
- In India, the Clopidogrel Price Index fell by 9.74% quarter-over-quarter, reflecting weaker tender restocking demand.
- The average Clopidogrel price for the quarter was approximately USD 37009.43/MT, with steady ex-works inventories.
- Domestic Clopidogrel Spot Price softened as distributors reduced elevated inventories, pressuring ex-factory offers thus materially.
- Clopidogrel Price Forecast points to mild recovery as routine formulation restocking and export enquiries firm.
- Clopidogrel Production Cost Trend remained stable as key starting materials and electricity tariffs were unchanged.
- Clopidogrel Demand Outlook stayed subdued short-term because fiscal-year procurement completed and private hospitals deferred purchases.
- Clopidogrel Price Index weakness persisted despite steady plant operations and normalised solvent availability across clusters.
- Manufacturer competition and tender-margin pressure forced producers to trim offers and prioritise immediate-volume demand fulfillment.
Why did the price of Clopidogrel change in March 2026 in APAC?
- Domestic tender completion and fiscal-year buying reduced immediate procurement volumes, weakening buyer pricing-power.
- Adequate plant inventories and uninterrupted production removed urgency, enabling sellers to concede discounts on volumes.
- Stable feedstock and energy costs prevented inflation, so weaker demand drove price declines.
Clopidogrel Prices in North America
- In North America, the Clopidogrel Price Index declined quarter-over-quarter, reflecting moderated procurement activity and sufficient supply conditions.
- Clopidogrel prices softened during the quarter as wholesalers and group purchasing organizations limited fresh buying amid adequate stock levels.
- Domestic Clopidogrel Spot Price eased as distributors focused on drawing down inventories, placing downward pressure on manufacturer quotations.
- Clopidogrel Price Forecast indicates a gradual firming trend supported by routine restocking cycles and stable downstream demand from healthcare providers.
- Clopidogrel Production Cost Trend remained steady, with limited fluctuations in input costs and relatively stable energy pricing.
- Clopidogrel Demand Outlook remained subdued in the short term due to completed contract cycles and cautious procurement strategies among hospital networks.
- Clopidogrel Price Index continued to face pressure despite consistent production rates and reliable supply chain conditions.
- Competitive supplier landscape and contract-driven pricing mechanisms encouraged manufacturers to adjust offers to maintain volume commitments.
Why did the price of Clopidogrel change in March 2026 in North America?
- Completion of procurement cycles among large healthcare buyers reduced immediate purchasing needs, weakening spot demand.
- Sufficient inventory levels across distribution channels reduced urgency for replenishment, strengthening buyer negotiation power.
- Stable production and input costs limited upward pricing pressure, allowing demand-side softness to drive the overall price decline.
Clopidogrel Prices in Europe
- In Europe, the Clopidogrel Price Index declined quarter-over-quarter, mirroring a softer procurement cycle across key markets.
- Clopidogrel prices trended lower through the quarter as distributor destocking and cautious purchasing behavior weighed on supplier negotiations.
- Domestic Clopidogrel Spot Price softened with wholesalers focusing on inventory optimization, leading to reduced ex-factory realizations.
- Clopidogrel Price Forecast further indicates a gradual stabilization as hospital tenders resume and export inquiries from adjacent regions improve.
- Clopidogrel Production Cost Trend remained largely stable, supported by balanced energy markets and minimal volatility in intermediate inputs.
- Clopidogrel Demand Outlook stayed muted in the near term due to completed public-sector tenders and slower replenishment cycles in private channels.
- Clopidogrel Price Index pressure persisted despite steady production rates and sufficient raw material availability across manufacturing hubs.
- Competitive pricing dynamics and tender-driven contracts compelled manufacturers to adjust offers to secure consistent off-take volumes.
Why did the price of Clopidogrel change in March 2026 in Europe?
- Completion of major healthcare tenders across several countries reduced immediate purchasing requirements, limiting spot demand.
- Elevated inventory levels among distributors and hospital networks decreased urgency for fresh procurement, increasing buyer leverage.
- Stable production costs meant pricing was primarily influenced by demand-side weakness rather than input-driven inflation.
For the Quarter Ending December 2025
Clopidogrel Prices in APAC
- In India, the Clopidogrel Price Index fell by 3.58% quarter-over-quarter, due to softer demand conditions.
- The average Clopidogrel price for the quarter was approximately USD 41001.04/MT, based on EXW volumes.
- Clopidogrel Spot Price tightened as warehouses reached working-minimum inventories, supporting sellers' pricing power, limiting discounts.
- Clopidogrel Price Forecast points to mild near-term firmness driven by hospital procurement and export inquiries.
- Clopidogrel Production Cost Trend shows upward pressure from intermediates and inland freight, offset by energy.
- Clopidogrel Demand Outlook remains constructive with Jan Aushadhi procurements and hospital tender cycles sustaining offtake.
- Export inquiries and port throughput influenced the Clopidogrel Price Index, keeping volatility low, upward bias.
- Major Indian producers operated near nameplate capacity, inventory rotation remained tight, supporting ex-works offers ahead.
Why did the price of Clopidogrel change in December 2025 in APAC?
- Sustained production near capacity and uncongested ports limited surplus, keeping domestic availability constrained versus demand.
- Firm hospital procurement and Jan Aushadhi tenders increased offtake, supporting modest upward pressure on prices.
- Rising inland freight and intermediate costs elevated ex-works manufacturing expenses, prompting producers to raise offers.
Clopidogrel Prices in North America
- Regional price indices moderately declined over the quarter due to cautious procurement and inventory adjustments.
- Spot prices softened as producers fulfilled export commitments and distributors managed stocks conservatively.
- Demand remained steady but cautious, with buyers awaiting clearer signals from hospital and formulary procurement cycles.
- Pharmaceutical distributors balanced inventory levels carefully, limiting aggressive restocking.
- Near-term forecast indicates potential moderate recovery supported by production turnarounds and improving downstream demand.
Why December 2025 Prices Changed
- Inventory positions and subdued offtake led to softer pricing conditions.
- Export/import shifts and logistics costs influenced supply distribution, affecting regional availability.
Clopidogrel Prices in Europe
- Europe’s price index slightly weakened as steady supply met mild contraction in downstream demand.
- Spot prices reflected mixed sentiment, with regional variations between central and southern markets.
- Demand outlook showed cautious optimism, with hospitals and manufacturers planning moderate restocking.
- Tender schedules and healthcare budgets influenced downstream offtake across EU markets.
- Price Forecast & Outlook
- Near-term forecast expects stable to firm pricing, supported by seasonal demand improvements and balanced production schedules.
Why December 2025 Prices Changed
- Steady supply inflows from multiple sources limited upward price pressure.
- Cautious demand and inventory adjustments by formulators tempered aggressive pricing shifts.
For the Quarter Ending September 2025
APAC
• In India, the Clopidogrel Price Index fell by 6.56% quarter-over-quarter, due to oversupply and weak demand.
• The average Clopidogrel price for the quarter was approximately USD 42524.99/MT as reported by spot indications.
• Clopidogrel Spot Price softened during the quarter as aggressive destocking and export offers pressured domestic quotations lower.
• Clopidogrel Production Cost Trend improved with lower feedstock costs, allowing suppliers to offer discounted volumes.
• Clopidogrel Demand Outlook remained cautious as formulation buyers delayed replenishment, limiting absorption of elevated inventories.
• Clopidogrel Price Forecast indicates modest seasonal recovery ahead, supported by maintenance shutdowns and festival-driven buying.
• Clopidogrel Price Index volatility reflected INR depreciation and freight reductions, influencing market sentiment and caution.
• Export demand and production diversions tightened domestic availability, supporting upward pressure on spot and contract prices.
Why did the price of Clopidogrel change in September 2025 in APAC?
• Elevated domestic manufacturing and PLI-driven oversupply created inventory glut, exerting downward pressure on September quotations.
• Reduced downstream purchasing and cautious formulation procurement limited demand, preventing absorption of excess market volumes.
• Lower feedstock costs and improved logistics reduced production and freight expenses, enabling sellers to cut prices strategically.
North America
• Clopidogrel Price Index exhibited a moderate decline quarter-over-quarter, influenced by fluctuating inventory positions and subdued offtake from downstream pharmaceutical formulators.
• Average Clopidogrel Price trended lower during the period, reflecting competitive offers amid cautious procurement across the U.S. and Canadian markets.
• Clopidogrel Spot Price softened as producers prioritized export commitments and local distributors reduced inventories to manage cash flow.
• Clopidogrel Production Cost Trend improved slightly with easing input costs and better plant operating rates, though energy price fluctuations created mixed cost dynamics.
• Clopidogrel Demand Outlook remained steady but cautious, as buyers awaited clearer signals from prescription drug demand and hospital purchasing cycles.
• Clopidogrel Price Forecast indicates a potential moderate recovery in the upcoming quarter, supported by scheduled production turnarounds and improved retail demand.
• Clopidogrel Price Index Volatility reflected changes in crude oil-linked feedstocks and domestic logistics costs, shaping short-term sentiment.
• Export and Import Flow Adjustments influenced supply distribution, occasionally tightening availability in certain states and supporting marginal price stabilization.
Europe
• Clopidogrel Price Index weakened slightly during the quarter amid steady supply inflows from regional and overseas producers, alongside mild demand contraction from formulators.
• Average Clopidogrel Price remained under pressure as distributors adjusted inventory levels following lower-than-expected pharmaceutical offtake in major EU markets.
• Clopidogrel Spot Price displayed mixed sentiment, with southern European markets facing weaker demand while central regions observed modest restocking.
• Clopidogrel Production Cost Trend was aided by lower raw material prices, although high utility and energy expenses continued to constrain margin recovery.
• Clopidogrel Demand Outlook suggested cautious optimism ahead, with hospitals and drug manufacturers planning moderate restocking before the winter season.
• Clopidogrel Price Forecast anticipates stable-to-firm pricing in the near term, supported by seasonal demand recovery and balanced production schedules.
• Clopidogrel Price Index Volatility was shaped by exchange rate fluctuations (EUR vs. USD) and varying freight conditions across intra-EU trade routes.
• Export Market Sentiment stayed mixed, as stronger Asian competition limited outbound sales while localized shortages lent some domestic price support.
For the Quarter Ending June 2025
North America
• The overall trend for Clopidogrel Bisulfate spot price in North America during Q2 2025 exhibits a downward trajectory, mirroring the declining pattern observed in the Indian market. Spot prices softened steadily through June 2025, ending the quarter at levels below peak Q1 values.
• The Clopidogrel Bisulfate price forecast for the next quarter indicates continued downward pressure due to the spillover effects of India’s surplus supply and easing production costs, supporting a bearish outlook on pricing strategy in North America.
• Clopidogrel Bisulfate Production cost trends within the quarter reflected modest reductions, driven by lowered raw material costs influenced by improved logistics and supply chain conditions originating from key bulk drug exporters such as India.
• Clopidogrel Bisulfate Demand outlook within the quarter remained cautious; while cardiovascular disease prevalence supports steady Clopidogrel consumption, procurement cycles elongated as buyers anticipated further price corrections.
• June 2025 witnessed notable price softening, triggered by Indian exporters aggressively pricing excess Clopidogrel APIs, which pressured North American manufacturers to adjust their pricing and inventory strategies.
• Regulatory scrutiny and compliance requirements continued to impose operational costs, moderating gains from lower production expenses and constraining manufacturers’ margin improvements.
• The competitive landscape saw intensified activity from generic players capitalizing on the lower spot price environment to expand market share.
• Supply tightness experienced earlier in the year eased due to improved API availability, slowing the urgency of stockpiling among distributors and formulators.
• Contract manufacturing organizations (CMOs) responded by enhancing manufacturing flexibility to adapt to fluctuating demand and pricing dynamics in the quarter.
• Forward procurement strategies became increasingly data-driven, with buyers leveraging market intelligence to optimize purchase timing amid volatile price movements.
APAC
• Clopidogrel Bisulfate spot price in APAC experienced a mixed trend in Q2 2025, with an overall marginal decline averaging approximately -0.31% quarter-over-quarter. Prices trended downward by June, reflecting influences from the Indian market’s significant supply expansion and inventory liquidation.
• The Clopidogrel Bisulfate price forecast for the next quarter suggests further downward pressure in APAC due to persistent supply glut and cautious demand behavior among end-users constrained by tighter healthcare budgets.
• Clopidogrel Bisulfate Production cost trends within the quarter benefited from improved raw material availability and reduced energy expenses, particularly in leading manufacturing hubs across India and China.
• Clopidogrel Bisulfate demand outlook within the quarter was tempered by strategic procurement pauses, with buyers balancing baseline cardiovascular demand against an oversupplied market and better pricing options.
• June 2025 saw a pronounced dip in spot prices as excess API inventory from Indian producers entered regional export markets, pressuring local manufacturers’ pricing strategies.
• Input cost deflation was a key driver in the production cost trend, with fermentative intermediates and solvents declining in price, enabling more competitive pricing for Clopidogrel APIs.
• Supply dynamics were affected by regulatory reforms and environmental audits in China, which constrained alternative API sources but were offset by Indian production capacity gains.
• Pharmaceutical players in the region adjusted inventories conservatively, preferring spot market purchases amid price weakness rather than long-term contract commitments.
• Export demand from Southeast Asian countries remained positive but slowed down due to buyers’ cautious stance in light of anticipated price falls.
• Manufacturing investments focused on capacity optimization and compliance enhancements to maintain quality standards while managing cost pressures.
Europe
• In Europe, the Clopidogrel Bisulfate spot price showed a downward trend in Q2 2025, consistent with the Indian market’s decline, with an average price decreasing considerably. By June, prices had weakened further due to eased pressure from global supply surpluses.
• The Clopidogrel Bisulfate price forecast for the next quarter indicates potential stabilization but limited upside, as European buyers adjust to increased API availability and stable production costs.
• Clopidogrel Bisulfate Production cost trends remained relatively stable, supported by competitive sourcing from Indian and regional suppliers, combined with efficient manufacturing operations adhering to stringent EU regulatory standards.
• Clopidogrel Bisulfate Demand outlook within the quarter was steady yet cautious, reflecting tight budget controls in European healthcare systems and moderate growth in chronic cardiovascular patient populations.
• June 2025 marked a period of increased buyer price sensitivity, with contract formulators reluctant to replenish large inventories amid low spot prices.
• The impact of Indian manufacturers’ stock liquidations was strongly felt across European markets, creating downward pressure on local market prices.
• Regulatory compliance costs remained a significant factor but were effectively managed through technological upgrades and streamlined quality assurance processes.
• European distributors leveraged the favorable price environment to optimize supply chain efficiencies, emphasizing just-in-time inventory strategies.
• Market competition intensified as generic manufacturers and biosimilar producers sought to capitalize on the reduced API cost base.
• Forward-looking procurement strategies integrated advanced analytics to forecast demand volatility and price movements in the evolving regulatory landscape.
